Skip to main content
Evidence Snapshot

Adenosine receptor A2b

CHEMBL255 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T08:50:38Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL255
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Adenosine receptor A2b as ChEMBL target CHEMBL255, mapped to UniProt P29275. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Adenosine receptor A2b
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL255
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P29275
Adenosine receptor A2b
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Adenosine receptor A2b matters

As of 2026-09-13

Adenosine receptor A2b is reviewed as Adenosine receptor A2b (UniProt P29275); Adenosine receptor A2b shows clinical signal disease relevance led by metastatic prostate cancer. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 7 approved drugs, 6716 compounds, and 730 assays, with lead potency reaching pChEMBL 10.1.

Disease context
metastatic prostate cancer

Adenosine receptor A2b shows clinical signal disease relevance led by metastatic prostate cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ETRUMADENANT.

Start review with metastatic prostate cancer because it currently carries clinical signal support. Linked drugs include ETRUMADENANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 6716 compounds, and 730 assays for this target. The dominant activity type is KI. CHEMBL4552275 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL4552275 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 10.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Adenosine receptor A2b matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P29275, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why metastatic prostate cancer is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

6716
Total Compounds
730
Total Assays
7
Approved Drugs
IC50: 2118.0, KI: 3419.0, EC50: 508.0, KD: 50.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4552275
 10.1 Ki —
No preferred name
CHEMBL5827075
 10.0 IC50 —
No preferred name
CHEMBL4450864
 9.9 Ki —
No preferred name
CHEMBL4464522
 9.8 Ki —
No preferred name
CHEMBL4540206
 9.8 Ki —

Approved Drugs

Structure Compound First Approval
ADENOSINE
CHEMBL477
 1989
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T08:50:38Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL255